Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LITMUS

Financiado

Cerrado

Liver Investigation Testing Marker Utility in Steatohepatitis

Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is chara... ver más

29/02/2024

UNEW

47M€

Presupuesto del proyecto: 47M€

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 57 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-02-29

IMI2-2016-09-05: IDENTIFICATION AND VALIDATION OF BI...

I+D

Cerrada hace 8 años

0% 33% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

57 Participantes

UNEW

2.99M€ | Lider

HISTOINDEX PTE LTD

Eli Lilly

1.93M€ | Participante

FFUL

56.97K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

mtFOIE GRAS mitoFOIE GRAS Non invasive Profiling of Mitochondrial Funct... 455K€ Cerrado

halt-RONIN Discovering chronic inflammation biomarkers that define key... 7M€ Cerrado

RENAISSANCE Advanced biomarker discovery for earlier diagnosis and impro... 150K€ Cerrado

PID2021-125394OA-I00 ESTADIFICACION NO INVASIVA DE LA ESTETATOHEPATITIS NO ALCOHO... 121K€ Cerrado

DeMILI NON INVASIVE DIAGNOSTIC TEST SERVICE FOR NON ALCOHOLIC FATT... 71K€ Cerrado

Duración del proyecto: 76 meses Fecha Inicio: 2017-10-09
Fecha Fin: 2024-02-29

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 47M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial). LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores